Literature DB >> 9918192

Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches.

L Costantino1, G Rastelli, P Vianello, G Cignarella, D Barlocco.   

Abstract

Despite recent advances both in the chemistry and molecular pharmacology of antidiabetic drugs, diabetes still remains a life-threatening disease, which tends to spread all over the world. The clinical profile of diabetic subjects is often worsened by the presence of several long-term complications, namely neuropathy, nephropathy, retinopathy, and cataract. Several attempts have been made to prevent or at least to delay them. The most relevant are reported in this review, including the development of compounds acting as aldose reductase inhibitors, anti-advanced glycation end-product drugs, free radical scavengers, vasoactive agents, essential fatty acid supplementation, and neurotropic growth factors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9918192     DOI: 10.1002/(sici)1098-1128(199901)19:1<3::aid-med2>3.0.co;2-7

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  16 in total

1.  Structural and thermodynamic studies of simple aldose reductase-inhibitor complexes.

Authors:  June M Brownlee; Erik Carlson; Amy C Milne; Erika Pape; David H T Harrison
Journal:  Bioorg Chem       Date:  2006-11-02       Impact factor: 5.275

2.  Discovery of novel PTP1B inhibitors with antihyperglycemic activity.

Authors:  Zhang Liu; Qian Chai; Yuan-yuan Li; Qiang Shen; Lan-ping Ma; Li-na Zhang; Xin Wang; Li Sheng; Jing-ya Li; Jia Li; Jing-kang Shen
Journal:  Acta Pharmacol Sin       Date:  2010-08       Impact factor: 6.150

Review 3.  Can drugs or micronutrients prevent cataract?

Authors:  J J Harding
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Aldose reductase-deficient mice develop nephrogenic diabetes insipidus.

Authors:  H T Ho; S K Chung; J W Law; B C Ko; S C Tam; H L Brooks; M A Knepper; S S Chung
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

5.  A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications.

Authors:  Jithan V Aukunuru; Gangadhar Sunkara; Surya P Ayalasomayajula; Jack DeRuiter; Randall C Clark; Uday B Kompella
Journal:  Pharm Res       Date:  2002-03       Impact factor: 4.200

6.  The relationship between red blood cell Na/K-ATPase activities and diabetic complications in patients with type 2 diabetes mellitus.

Authors:  Bayram Koc; Vedat Erten; M Ilker Yilmaz; Alper Sonmez; I Hakki Kocar
Journal:  Endocrine       Date:  2003-08       Impact factor: 3.633

7.  Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor.

Authors:  Gangadhar Sunkara; Surya P Ayalasomayajula; Jack DeRuiter; Uday B Kompella
Journal:  Brain Res Bull       Date:  2009-09-15       Impact factor: 4.077

8.  Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor.

Authors:  Gangadhar Sunkara; Surya P Ayalasomayajula; Cheruku S Rao; Jonathan L Vennerstrom; Jack DeRuiter; Uday B Kompella
Journal:  J Pharm Pharmacol       Date:  2004-03       Impact factor: 3.765

9.  Proteome wide reduction in AGE modification in streptozotocin induced diabetic mice by hydralazine mediated transglycation.

Authors:  Suresh K Kesavan; Shweta Bhat; Sandeep B Golegaonkar; Mashanipalya G Jagadeeshaprasad; Arati B Deshmukh; Harshal S Patil; Santosh D Bhosale; Mahemud L Shaikh; Hirekodathakallu V Thulasiram; Ramanamurthy Boppana; Mahesh J Kulkarni
Journal:  Sci Rep       Date:  2013-10-15       Impact factor: 4.379

Review 10.  Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors/Antioxidants as Promising Drugs for the Treatment of Diabetic Complications.

Authors:  Lucia Kovacikova; Marta Soltesova Prnova; Magdalena Majekova; Andrej Bohac; Cimen Karasu; Milan Stefek
Journal:  Molecules       Date:  2021-05-12       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.